ADAURA
Tagrisso Approved as First Adjuvant Treatment of EGFR-Mutated NSCLC
The FDA approved osimertinib (Tagrisso, AstraZeneca) for adjuvant therapy after tumor resection in adults with ...
JANUARY 3, 2021
Thoughts on Adjuvant Osimertinib: The ADAURA Trial Report
Nasser Hanna, MD, and Steven Vogl, MD, discuss the findings from the ADAURA NSCLC trial presented at ASCO 2020 and ...
SEPTEMBER 21, 2020
Load more